Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature

被引:3
作者
Nasca, Vincenzo [1 ]
Frezza, Anna Maria [1 ]
Morosi, Carlo [2 ]
Buonomenna, Ciriaco [2 ]
Parafioriti, Antonina [3 ]
Zappala, Giorgio [4 ]
Bini, Federica [5 ]
Casali, Paolo Giovanni [1 ,6 ]
Loppini, Mattia [7 ,8 ]
Stacchiotti, Silvia [1 ]
机构
[1] Carattere Sci IRCCS Ist Nazl Tumori, Fdn Inst Ricovero & Cura, Dept Med Oncol, Milan, Italy
[2] Carattere Sci IRCCS Ist Nazl Tumori, Fdn Inst Ricovero & Cura, Dept Radiol, Milan, Italy
[3] Aziende Socio Sanitarie Territoriali ASST Pini, Centri Traumatol Ortoped CTO, Dept Pathol, Milan, Italy
[4] Osped Papa Giovanni XXIII, Dept Orthopaed Surg, Bergamo, Italy
[5] Osped Papa Giovanni XXIII, Dept Med Oncol, Bergamo, Italy
[6] Univ Milan, Dept Oncol & Hemato oncol, Milan, Italy
[7] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[8] Carattere Sci IRCCS Humanitas Res Hosp, Dept Orthopaed Surg, Inst Ricovero & Cura, Milan, Italy
关键词
denosumab; giant cell tumor of bone; sarcoma; atypical femur fracture; bone tumor; FEMORAL FRACTURES; RECEPTOR ACTIVATOR; OSTEOPOROSIS; LIGAND;
D O I
10.3389/fonc.2022.953149
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Giant cell tumor of the bone (GCTB) is a locally aggressive neoplasm where surgery is often curative. However, it can rarely give rise to distant metastases. Currently, the only available active therapeutic option for unresectable GCTB is denosumab, an anti-RANKL monoclonal antibody that dampens the aggressive osteolysis typically seen in this disease. For advanced/metastatic GCTB, denosumab should be continued lifelong, and although it is usually well tolerated, important questions may arise about the long-term safety of this drug. In fact, uncommon but severe toxicities can occur and eventually lead to denosumab discontinuation, such as atypical fracture of the femur (AFF). The optimal management of treatment-related AFF is a matter of debate, and to date, it is unknown whether reintroduction of denosumab at disease progression is a clinically feasible option, as no reports have been provided so far. Hereinafter, we present a case of a patient with metastatic GCTB who suffered from AFF after several years of denosumab; we describe the clinical features, orthopedic treatment, and oncological outcomes, finally providing the first evidence that denosumab rechallenge after AFF occurrence may be a safe and viable option at GCTB progression.
引用
收藏
页数:7
相关论文
共 44 条
[41]   Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society [J].
van de Laarschot, Denise M. ;
McKenna, Malachi J. ;
Abrahamsen, Bo ;
Langdahl, Bente ;
Cohen-Solal, Martine ;
Guanabens, Nuria ;
Eastell, Richard ;
Ralston, Stuart H. ;
Zillikens, M. Carola .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (05)
[42]   Giant cell tumour of bone in the denosumab era [J].
van der Heijden, Lizz ;
Dijkstra, P. D. Sander ;
Blay, Jean-Yves ;
Gelderblom, Hans .
EUROPEAN JOURNAL OF CANCER, 2017, 77 :75-83
[43]  
Wang Kemble, 2011, J Orthop Surg (Hong Kong), V19, P89
[44]   Giant cell tumour of bone: morphological, biological and histogenetical aspects [J].
Werner, Mathias .
INTERNATIONAL ORTHOPAEDICS, 2006, 30 (06) :484-489